• WedgeGlobal creative AOR: Publicis Health (Saatchi Wellness, Digitas Health, Razorfish Health, etc.) — AbbVie has multi-year integration with Publicis Health since post-2013 Abbott spin-off
• WhyImmunology direct competitors: Novartis (Cosentyx — IL-17, predecessor in psoriasis), Lilly (Taltz — IL-17), J&J (Stelara — IL-12/23, Tremfya — IL-23 direct Skyrizi competitor), Pfizer (Xeljanz, Cibinqo — JAKs competing with Rinvoq), Bristol-Myers Squibb (Sotyktu — TYK2 in psoriasis). Oncology/Hematology: AstraZeneca (Calquence, Imfinzi), BeiGene (Brukinsa). Aesthetics direct competitors: Galderma (Restylane fillers, Dysport), Merz Aesthetics (Xeomin, Belotero), Evolus (Jeuveau).

1. W1Global creative AOR: Publicis Health (Saatchi Wellness, Digitas Health, Razorfish Health, etc.) — AbbVie has multi-year integration with Publicis Health since post-2013 Abbott spin-off
2. W2Skyrizi + Rinvoq are the FASTEST-GROWING pharma brands globally (each on path to $10B+ peak sales) — peak Taiwan marketing investment phase NOW
3. W3Humira biosimilar defense is largely DONE in mature markets — TW Humira marketing is winding down
4. W4Allergan Aesthetics (Botox Cosmetic, Juvederm) is a SEPARATE pitch surface — CONSUMER-LED, not Rx-restricted, has separate agency landscape. Historically Allergan Aesthetics used Publicis (Razorfish, Digitas) plus consumer beauty agencies. AbbVie integration may have shifted; Aesthetics is the highest-DTC pharma sub-surface in TW.
5. W5Vraylar (Cariprazine — schizophrenia, bipolar I depression) major US growth driver — TW launch timing TBD
6. W6Imbruvica facing CLL competitive pressure from BeiGene Brukinsa, AstraZeneca Calquence

• Immunology direct competitors: Novartis (Cosentyx — IL-17, predecessor in psoriasis), Lilly (Taltz — IL-17), J&J (Stelara — IL-12/23, Tremfya — IL-23 direct Skyrizi competitor), Pfizer (Xeljanz, Cibinqo — JAKs competing with Rinvoq), Bristol-Myers Squibb (Sotyktu — TYK2 in psoriasis). Oncology/Hematology: AstraZeneca (Calquence, Imfinzi), BeiGene (Brukinsa). Aesthetics direct competitors: Galderma (Restylane fillers, Dysport), Merz Aesthetics (Xeomin, Belotero), Evolus (Jeuveau).
• LOW (Rx Pharma) / MEDIUM (Aesthetics potential). AbbVie Rx creative is consolidated under Publicis Health globally — WPP (Ogilvy Health, VML Health) has limited central Rx scope. WPP Taiwan would need to win at therapy-area level (Immunology BU especially for Skyrizi/Rinvoq launches). ALLERGAN AESTHETICS is the highest-leverage WPP wedge — consumer-DTC, beauty-adjacent (where WPP's beauty-vertical strength matters: VML, Ogilvy, GroupM has strong beauty/consumer-luxury experience via L'Oréal, Estée Lauder etc.), separate from Rx restrictions, fast-moving social-first creative. Aesthetics is the BU most likely to break from Publicis Health pharma structure.
• Skyrizi Taiwan NHI reimbursement expansions (psoriasis → PsA → IBD)
• Rinvoq Taiwan NHI expansions across indications
• Allergan Aesthetics Taiwan campaign launches (Botox Cosmetic, Juvederm) — consumer / KOL-led
• AbbVie Taiwan GM changes (vendor review trigger)
• Global AbbVie quarterly earnings — Immunology BU spend disclosures, Aesthetics performance
• Humira biosimilar share-loss data (signals shift of spend to next-gen Skyrizi/Rinvoq)

• General Manager — AbbVie Taiwan (incumbent unverified)GM AbbVie Taiwan

  since

  GM rotates 3-5 years. Reports to AbbVie International APAC. LinkedIn/press diligence required to confirm current incumbent.

  Source ↗
• BU Lead — Immunology (HIGHEST PRIORITY)Immunology BU Lead — AbbVie Taiwan

  since

  Largest BU. Skyrizi + Rinvoq launches drive bulk of marketing budget through 2026. Single most important agency-relationship target in AbbVie TW Rx.

  Source ↗
• BU Lead — Allergan Aesthetics Taiwan (CONSUMER-DTC, SEPARATE WEDGE)GM / Marketing Lead — Allergan Aesthetics Taiwan

  since

  SEPARATE consumer-DTC pitch surface. Beauty/medical-aesthetic clinic channel. KOL-driven. Highest WPP wedge potential — consumer/beauty agency capabilities applicable.

  Source ↗

AbbVie Taiwan (台灣艾伯維) is mid-tier MNC pharma in Taiwan (top 8-12 by Rx revenue) but with critical strategic context: Humira biosimilar erosion is the central global story (Humira lost US patent exclusivity 2023; multiple biosimilars in TW; revenue stepping down ~30-40% globally). AbbVie's playbook is to MIGRATE Humira patients to next-gen IL-23 (Skyrizi) and JAK (Rinvoq) — both of which are growing 50%+ annually globally. In TW: Skyrizi and Rinvoq launches across IBD (Crohn's, ulcerative colitis), psoriasis, PsA, AS, RA, atopic dermatitis are the BIG marketing investment waves 2024-2026. ALSO: AbbVie inherits significant CONSUMER footprint via Allergan Aesthetics (Botox Cosmetic, Juvederm) — this is FULL CONSUMER DTC, not Rx-restricted, sold through medical-aesthetic clinics (#1 medical-aesthetic market in Taiwan by spend). Estimated NT$200-400M Rx ad spend, PLUS separately significant Allergan Aesthetics consumer spend (likely NT$150-300M).

No campaigns surfaced in research.

No decision-makers identified.

AbbVie Taiwan reports into AbbVie International — Asia Pacific (Singapore hub). General Manager rotates 3-5 years. Commercial structure: Immunology BU (largest — Humira/Skyrizi/Rinvoq), Oncology/Hematology BU, Neuroscience BU (incl. Botox Therapeutic), Eye Care BU, AESTHETICS BU (Allergan Aesthetics — runs SEPARATE from Rx, consumer-focused, separate agency partners likely). The Aesthetics BU is structurally and culturally distinct — it operates like a beauty/consumer brand within a pharma holding.